Blueberry Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 15
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $18.5M
Latest Deal Amount
  • Investors
  • 6

Blueberry Therapeutics General Information

Description

Developer of therapeutic drugs designed to help in the treatment of common dermatological disorders. The company's drugs are produced through a nano polymer drug delivery platform which formulates candidate drugs to enhance delivery into cells and tissue, and to tackle the healthcare needs for antibiotic resistance, enabling patients to combat bacterial infection by neutralizing resistance in combination with standard antibiotics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Mereside, Alderley Park
  • Cheshire
  • Alderley Edge SK10 4TG
  • England, United Kingdom
+44 01625 000000

Blueberry Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Blueberry Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 29-Jan-2021 $18.5M 000.00 Completed Generating Revenue
4. Later Stage VC 19-Jun-2019 00.000 000.00 000.00 Completed Generating Revenue
3. Later Stage VC 13-Dec-2017 00.000 00.00 000.00 Completed Generating Revenue
2. Early Stage VC 05-May-2016 $4.31M $5.79M Completed Generating Revenue
1. Angel (individual) 08-Apr-2015 $1.49M $1.49M 00.000 Completed Generating Revenue
To view Blueberry Therapeutics’s complete valuation and funding history, request access »

Blueberry Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.00
Ordinary 425,903 $0.000014 $6.52 $6.52 1x $6.52 13.65%
To view Blueberry Therapeutics’s complete cap table history, request access »

Blueberry Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
John Ridden Ph.D Co-Founder, Chief Executive Officer & Board Member
David Cook Ph.D Chief Scientific Officer
Mark Hollingworth Finance Director
Tony Sedgwick Advisor to the Board
Alex O'Neill Scientific Advisor
You’re viewing 5 of 10 executive team members. Get the full list »

Blueberry Therapeutics Board Members (7)

Name Representing Role Since
Adrian Howd Ph.D Blueberry Therapeutics Board Member 000 0000
Andrew Kay Self Chairman 000 0000
Gareth King Ph.D Catapult Ventures Board Observer 000 0000
Huaizheng Peng Ph.D Self Board Member 000 0000
John Ridden Ph.D Blueberry Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Blueberry Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blueberry Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
A&B (HK) Company Corporation Minority 000 0000 000000 0
China Medical System Corporation Minority 000 0000 000000 0
Medical Incubator Japan Venture Capital Minority 000 0000 000000 0
Omar Ibrahimi Angel (individual) Minority 000 0000 000000 0
Catapult Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »